Matteo Marzaroli

Anesthesiology and Intensive Care resident doctor @SanRaffaeleMI

Follow @SRanesthesiaICU

[Alessandro Belletti @alebelletti1]

Could pirfenidone prevent pulmonary fibrosis in #ARDS patients?

Our multicenter #PIONEER RCT will answer this question!

Full methodological manuscript now available at https://t.co/I4nqKJdoFG

@SRAnesthesiaICU @GiacomoMonti @giovannilandoni @marzarolimd @manazzamarcoMD

[Giovanni Landoni, MD @giovannilandoni]

@SRAnesthesiaICU @MyUniSR @SanRaffaeleMI @marzarolimd @Barbara58342884 @IChiodega @GiacomoMonti @MarinaPieri5 @ElenaMoizo @BaiardoMartina @stefano_turi @mgcalabroMD @md_monaco @alebelletti1 @tscquizzato @LosiggioRosario #mercytrial presented by @marzarolimd

[San Raffaele Anesthesia and Intensive Care @SRAnesthesiaICU]

7 new anesthesiologists graduated today in Milan @MyUniSR @SanRaffaeleMI

101 are queuing up

@marzarolimd @Barbara58342884 @IChiodega

[San Raffaele Anesthesia and Intensive Care @SRAnesthesiaICU]

10/

It's our honor to publish the results of #MERCYtrial in JAMA @JAMA_current: Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis

🔗 https://t.co/MEAGJNM2ga

#FOAMcc

[San Raffaele Anesthesia and Intensive Care @SRAnesthesiaICU]

We've just presented and published a multicenter RCT at #CCR23 and in @JAMA_current!

Continuous vs Intermittent Meropenem Administration in Critically Ill Patients with Sepsis: The #MERCYtrial!

🔗 https://t.co/MEAGJNM2ga

This 🧵 will explain the study in detail /11

#FOAMcc

[JAMA @JAMA_current]

Editorial: "Monti and colleagues are to be commended for their well-designed and well-executed contribution to the controversial literature assessing dosing of β-lactam antibiotics in critically ill patients."

https://t.co/RSrALqMRoM

#CCR23

[JAMA @JAMA_current]

Continuous administration of meropenem, compared with intermittent administration, does not improve clinically relevant outcomes in critically ill patients with #sepsis.

https://t.co/eJ9zdGI4k2

#CCR23

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

It is my honor to work with the excellent team of this fantastic randomized clinical trial.
Every piece I learned during the manuscript writing process is invaluable.

I appreciate all the people involved in this study.
#MERCYtrial
#CCR23

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

Primary outcome: a composite of mortality or new emergence of PDR/XDR bacteria at day 28

No significant difference in the primary outcome, each component of the primary outcome
#CCR23 #MERCYtrial

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

Infographic of the trial design
Both groups received an initial loading dose (1g of meropenem).
Double-dummy administration

Primary outcome: a composite of death or PDR/XDR bacteria emergence at day 28

Culture collection schedule

#CCR23

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

A previous meta-analysis of RCTs showed a decreased mortality when beta-lactams are administered continuously, but there are several risks of bias.

So, we designed and performed #MERCYtrial, a multicenter randomized clinical trial.

#CCR23

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

Time above MIC is an important determinant for beta-lactams, including meropenem.
So, continuous infusion of meropenem is likely to exert efficacy compared with intermittent administration.

#CCR23 @CritCareReviews

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

THE SESSION of #MERCYtrial HAS STARTED!
@giovannilandoni @GiacomoMonti @SRAnesthesiaICU

#CCR23

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🔥🆕️MERCY RCT🆕️🔥
Continuous administration of meropenem, compared with intermittent administration, does NOT improve clinically relevant outcomes in critically ill patients with sepsis. #IDTwitter
https://t.co/sAHFbEVxvY

[Orlando RPN @OrlandoRPN]

Meropenem en infusión 🆚 intermitente en pacientes con Sepsis 💊 🦠

No hay diferencias en mortalidad 🟰

https://t.co/Bi7m4vvBHZ

[小谷祐樹 Yuki Kotani｜集中治療医 @YukiKotani5]

From 13:30 tomorrow (GMT), Prof. @GiacomoMonti & Prof. @giovannilandoni from @SRAnesthesiaICU will present #MERCYtrial results.

Looking forward to their presentation, the editorial from @FlaviaSepsis, and the comments from great panelists.

PLEASE DON'T MISS IT😉
#CCR23

[Karim Brohi @karimbrohi]

UK-REBOA results:

REBOA increased mortality at 90 days and at all interim time points.

REBOA increased deaths due to bleeding at 3 hours and 90 days.

REBOA substantially delayed time to definitive haemorrhage control.

💢🎈💢

#ccr23

[NEJM @NEJM]

Late breaking at #CCR23: In the PATCH-Trauma trial involving adults with major trauma, treatment with tranexamic acid did not result in a greater number of patients surviving with a favorable functional outcome at 6 months than placebo. https://t.co/i8fu34ReCB